Cargando…

Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

BACKGROUND: Low density lipoprotein cholesterol (LDL-C) and low grade arterial inflammation are key pathogenic factors for atherosclerosis and its manifestation, cardiovascular disease (CVD). OBJECTIVE: In this narrative review we assessed if decreasing LDL-C levels or inflammation or both is more e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reklou, Andromachi, Doumas, Michael, Imprialos, Konstantinos, Stavropoulos, Konstantinos, Patoulias, Dimitris, Athyros, Vasilios G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2018
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897979/ https://www.ncbi.nlm.nih.gov/pubmed/29785212 http://dx.doi.org/10.2174/1874192401812010029

Ejemplares similares

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data
por: Athyros, Vasilios G., et al.
Publicado: (2020)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

COVID-19: The Waterloo of governments, healthcare systems, and large health organizations
por: Doumas, Michael, et al.
Publicado: (2020)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
por: Patoulias, D., et al.
Publicado: (2022)

Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19
por: Patoulias, D., et al.
Publicado: (2022)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension
por: Papademetriou, Vasilios, et al.
Publicado: (2019)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
por: Athyros, Vasilios Gabriel, et al.
Publicado: (2016)

Off target effects of statins shape total mortality?
por: Athyros, Vasilios G., et al.
Publicado: (2016)

Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus
por: Lessey, Gayatri, et al.
Publicado: (2019)

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
por: Tziomalos, Konstantinos, et al.
Publicado: (2011)

Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Recent advances in understanding and managing resistant/refractory hypertension
por: Doumas, Michael, et al.
Publicado: (2020)

Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus
por: Papageorgiou, Christos, et al.
Publicado: (2021)

Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
por: Tziomalos, Konstantinos, et al.
Publicado: (2006)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Dealing with Pheochromocytoma during the First Trimester of Pregnancy
por: Kiroplastis, Konstantinos, et al.
Publicado: (2015)

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
por: McCormack, Terry, et al.
Publicado: (2016)

Editorial: Cardiovascular diseases in autoimmune diseases: Dyslipidemia and vascular inflammation
por: Solow, E. Blair, et al.
Publicado: (2022)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease
por: Lin, Qiuzhen, et al.
Publicado: (2021)

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?
por: Katsiki, Niki, et al.
Publicado: (2013)

Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension
por: Papademetriou, Vasilios, et al.
Publicado: (2011)

circ_0003204 Regulates Cell Growth, Oxidative Stress, and Inflammation in ox-LDL-Induced Vascular Endothelial Cells via Regulating miR-942-5p/HDAC9 Axis
por: Wan, Huan, et al.
Publicado: (2021)

Circulating Vascular Adhesion Protein-1 Level Predicts the Risk of Cardiovascular Events and Mortality in Hemodialysis Patients
por: Kim, Dae Kyu, et al.
Publicado: (2021)

Effects of BMI and LDL-cholesterol change pattern on cardiovascular disease in normal adults and diabetics
por: Youk, Tae Mi, et al.
Publicado: (2020)

The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events
por: Maierean, Serban, et al.
Publicado: (2022)

Systemic and local vascular inflammation and arterial reactive oxygen species generation in patients with advanced cardiovascular diseases
por: Sulicka-Grodzicka, Joanna, et al.
Publicado: (2023)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

ODP138 Age-related Associations of LDL Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-based Cohort Study
por: Kim, Min-Ju, et al.
Publicado: (2022)

Vascular Senescence in Cardiovascular and Metabolic Diseases
por: Katsuumi, Goro, et al.
Publicado: (2018)

Role of Cardiovascular Magnetic Resonance to Assess Cardiovascular Inflammation
por: Filomena, Domenico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t7sub0nbg8ru8ja0e4fqg4cv1d